

## DAFTAR PUSTAKA

- Aldossary, S.A., 2019. Review on Pharmacology of Cisplatin: Clinical Use , Toxicity and Mechanism of Resistance of Cisplatin 12, 7–15.
- Aliyah, N., Pranggono, E., Andriyoko, B., 2016. Kanker Paru: Sebuah Kajian Singkat. *Indones. J. Chest Emerg. Med.* 4, 28–32.
- Arjoso, S., 2020. Atlas Tembakau Indonesia Tahun 2020. *Tob. Control Support Center-Ikatan Ahli Kesehat. Masy. Indones.* 1–60.
- Azar, I., Yazdanpanah, O., Jang, H., Austin, A., Kim, S., Chi, J., Alkassis, S., Saha, B.K., Chopra, A., Neu, K., Mehdi, S., Mamdani, H., 2022. Comparison of Carboplatin with Cisplatin in Small Cell Lung Cancer in US Veterans. *JAMA Netw. Open* 5, E2237699. <https://doi.org/10.1001/jamanetworkopen.2022.37699>
- Bouchard, L.C., Aaronson, N., Gondek, K., Cella, D., 2018. Cancer symptom response as an oncology clinical trial end point. *Expert Rev. Qual. Life Cancer Care* 3, 35–46. <https://doi.org/10.1080/23809000.2018.1483193>
- Dwilovianita, Y., 2022. *Jurnal Penelitian Perawat Profesional* 4, 17–26.
- Epidemiologi, P.D.A.N., n.d. kanker paru PDPI-1.
- erlinda rara, lia kurniasari, 2021. Hubungan Antara Usia , Pendidikan , dan Pekerjaan dengan Kejadian Kanker Payudara pada Wanita di Kalimantan Timur 2, 1937–1943.
- Ettinger, D.S., Wood, D.E., Aisner, D.L., Akerley, W., Bauman, J.R., Bharat, A., Bruno, D.S., Chang, J.Y., Chirieac, L.R., D’Amico, T.A., Dilling, T.J., 2020. NCCN Clinical Guidelines in Oncology: Non-Small Cell Lung Cancer. *Natl. Compr. Cancer Netw.* 3, 1–240.
- García, G., Nicolás, G., Casariego, N., Julia, G., Nazco, V., 2017. Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non- squamous non-small-cell lung cancer in Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patien 41. <https://doi.org/10.7399/fh.2017.41.1.10142>
- Griesinger, F., Korol, E.E., Kayaniyil, S., Varol, N., Ebner, T., Goring, S.M., 2019. Lung Cancer Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer : A meta-analysis. *Lung Cancer* 135, 196–204. <https://doi.org/10.1016/j.lungcan.2019.07.010>
- Hale, O., Patterson, K., Lai, Y., Meng, Y., Li, H., Godwin, J.L., Moreno, B.H., Mamtani, R., 2021. Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1 e positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States. *Clin. Genitourin. Cancer* 19, e17–e30. <https://doi.org/10.1016/j.clgc.2020.07.006>
- Hospital, A.B., Hadiningsih, H., 2015. Analisis Besaran Biaya Obat Beberapa

Penyakit Rawat Jalan dan Faktor- Faktor yang Mempengaruhi di Rs. Awal Bros Bekasi Tahun 2014. *J. Adm. Rumah Sakit Indones.* 2, 53–63. <https://doi.org/10.7454/arsi.v2i1.2188>

Hotimah, H., 2018. HUBUNGAN KETEPATAN OBAT DENGAN KEBERHASILAN TERAPI PADA PASIEN HIPERTENSI DENGAN KOMPLIKASI DI RSD dr. SOEBANDI JEMBER.

Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M., Tanimoto, M., 2004. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. *J. Clin. Oncol.* 22, 3852–3859. <https://doi.org/10.1200/JCO.2004.02.109>

Huang, C., Cheng, M., Lee, N., Huang, H., Lee, W., Chang, W., Wang, P., 2020. Comparing Paclitaxel – Carboplatin with Paclitaxel – Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous- Type Tubo-Ovarian Cancer.

paolo Maione, F. perrone, 2015. Pretreatment Quality of Life and Functional Status Assessment Significantly Predict Survival of Elderly Patients With Advanced Non – Small-Cell Lung Cancer Receiving Chemotherapy : A Prognostic Analysis of the Multicenter Italian Lung Cancer in the Elderl 23, 6865–6872. <https://doi.org/10.1200/JCO.2005.02.527>

Pawel, D.J., Puskin, J.S., 2004. The U.S. Environmental Protection Agency’s assessment of risks from indoor radon. *Health Phys.* 87, 68–74. <https://doi.org/10.1097/00004032-200407000-00008>

Pritami, A.A., Soemarwoto, R.A.S., Wintoko, R., 2022. Faktor Risiko Kanker Paru : Tinjauan Pustaka. *J. Agromedicine* 9, 120–123.

Purba, A., Wibisono, B., 2015a. Pola Klinis Kanker Paru Rsup Dr. Kariadi Semarang Periode Juli 2013 - Juli 2014. *J. Kedokt. Diponegoro* 4, 389–398.

Purba, A., Wibisono, B., 2015b. Pola Klinis Kanker Paru Rsup Dr. Kariadi Semarang Periode Juli 2013 - Juli 2014. *J. Kedokt. Diponegoro* 4, 389–398.

Putriani, F.A., Kholis, F.N., Purwoko, Y., 2019. Perbedaan Faktor Risiko Penderita Adenokarsinoma Paru Dengan Mutasi Egfr Dan Non Mutasi Egfr. *Diponegoro Med. J. (Jurnal Kedokt. Diponegoro)* 8, 214–221.

Ridwanuloh, A.M., 2016. Menengok Peran Pemeriksaan Mutasi Gen Bagi Penderita Kanker Paru. *Biotrends* 7, 5–8.

Society, E., n.d. Kanker Paru Bukan Sel Kecil ?

Steliga, M.A., Dresler, C.M., 2011. Epidemiology of lung cancer: smoking, secondhand smoke, and genetics. *Surg. Oncol. Clin. N. Am.* 20, 605–618. <https://doi.org/10.1016/j.soc.2011.07.003>

Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA. Cancer J. Clin.* 71, 209–249. <https://doi.org/10.3322/caac.21660>

- Supartono, agus suryanto, 2012. Faktor-faktor yang Mempengaruhi Ketahanan Hidup Satu Tahun 1, 25–31.
- Tezel, G.G., Şener, E., Aydın, Ç., Önder, S., 2017. Prevalence of Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer in Turkish Population 567–571. <https://doi.org/10.4274/balkanmedj.2017.0297>
- Ueno, T., Toyooka, S., Suda, K., Soh, J., Yatabe, Y., Miyoshi, S., Matsuo, K., Mitsudomi, T., 2012. Lung Cancer Impact of age on epidermal growth factor receptor mutation in lung cancer. *Lung Cancer* 78, 207–211. <https://doi.org/10.1016/j.lungcan.2012.09.006>
- Vineis, P., Alavanja, M., Buffler, P., Fontham, E., Franceschi, S., Gao, Y.T., Gupta, P.C., Hackshaw, A., Matos, E., Samet, J., Sitas, F., Smith, J., Stayner, L., Straif, K., Thun, M.J., Wichmann, H.E., Wu, A.H., Zaridze, D., Peto, R., Doll, R., 2004. Tobacco and cancer: recent epidemiological evidence. *J. Natl. Cancer Inst.* 96, 99–106. <https://doi.org/10.1093/jnci/djh014>
- Wahyuningsih, I.S., Ikhsan, K.N., 2018. Nyeri Pada Pasien Kanker Yang Menjalani Kemoterapi Pain in cancer patients undergoing chemotherapy 133–137.
- Whittle, J., 2016. Health Administration data 9, 702–709. <https://doi.org/10.1097/JTO.000000000000146>. Cisplatin
- Wulandari, A., Monalisa, S., Zaini, J., 2019. Analisis Biaya Kemoterapi Lini Pertama Pada Pasien Kanker Paru di Rumah Sakit Persahabatan Jakarta Timur Periode Tahun 2016. *Sainstech Farma* 12, 85–92.